Medical Approaches to Weight-Centric Management of Obese Patients with Type 2 Diabetes
The traditional approach to management of type 2 diabetes has been targeting both glycemic control and associated risk factors that drive cardiovascular disease risk (blood pressure, dyslipidemia, pro-thrombotic tendency). The primary focus of this chapter is to explore the role of medical approaches (as opposed to surgical approaches) using lifestyle intervention to achieve weight management as a pathway to improving the metabolic profile, symptoms, and functionality of patients with type 2 diabetes. The chapter will review the evidence for health benefit from medically induced weight loss in persons with type 2 diabetes, and will limit its scope to interventions that use lifestyle alone, without adjunctive medications.
KeywordsType 2 diabetes Glycemic control Lifestyle intervention Metabolic profile
- 1.Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, Davidson MB, Einhorn D, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez G, Davidson MH, American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists’ comprehensive diabetes management algorithm 2013. Endocr Pract. 2013;19 Suppl 1:1–48.CrossRefGoogle Scholar
- 7.Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacologic management of obesity: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342–62.Google Scholar
- 22.Crosby. Manual for the IWQOL-LITE measure. www.qualityoflifeconsulting.com. Accessed 10 Sept 2014.
- 27.Foy CG, Lewis CE, Hairston KG, The Look AHEAD Research Group, et al. Intensive lifestyle intervention improves physical function among obese adults with knee pain: findings from the Look AHEAD trial. Obesity. 2011;19:83–93. Erratum, Obesity (Silver Spring) 2011;19:233.PubMedPubMedCentralCrossRefGoogle Scholar
- 32.Espeland MA, Glick HA, Bertoni A et al., the Look AHEAD Research Group. Impact of an intensive lifestyle intervention on use and cost of medical services among overweight and obese adults with Type 2 diabetes. Diabetes Care. 2014;37(9):2548–56.Google Scholar
- 35.Hollander P, Gupta AK, Plodkowski R, The COR-Diabetes Study Group, et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36(12):4022–9.PubMedPubMedCentralCrossRefGoogle Scholar
- 36.FDA Briefing Document NDA 206321. LIraglutide 3.0 mg. Endocrinologic and Metabolic Advisory Committee. 11 Sept 2014. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM413317.pdf. Accessed 25 Sept 2014.